Andrew Mitchell

The Department has been working with suppliers to address current supply issues with Creon, which is used by patients with conditions such as cystic fibrosis and certain cancers including pancreatic cancer. The supply issues with Creon are impacting countries throughout Europe and have been caused by limited availability of raw ingredients and manufacturing capacity constraints to produce volumes needed to meet demand. These issues have resulted in knock-on supply disruptions of alternative pancreatic enzyme replacement therapy medications. The Department is continuing to work with all suppliers of pancreatic enzyme replacement therapy to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.

The supplier of Creon has advised that they expect to have regular supplies released each month going forward and are working to increase the quantities released. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules which pharmacists can use to restrict supply to one month at a time to ensure more patients have access to it whilst stock is limited.

We have worked closely with colleagues in NHS England to issue comprehensive guidance to healthcare professionals about these supply issues and encourage sharing of local solutions. The guidance provides advice on how to manage patients whilst there is disruption to supply and is being kept under review, with updates made as necessary.

His Majesty's Government continues to hold discussions with the Portuguese Government, as part of our efforts to ensure the proceeds from the sale of Chelsea FC reach humanitarian causes in Ukraine as quickly as possible, in line with the UK's unilateral declaration. The Government is fully committed to that position, as part of our iron-clad support for Ukraine.

The UK Government continues to hold discussions with the European Commission, as part of our efforts to ensure the proceeds from the sale of Chelsea FC reach humanitarian causes in Ukraine as quickly as possible, in line with the UK's unilateral declaration. The Government is fully committed to that position, as part of our iron-clad support for Ukraine.

We are grateful to the Honourable member for bringing this matter to our attention. We apologise for the delay. A response will be issued in due course.

On day one in office, the Foreign Secretary commissioned a thorough review into Israel's compliance with International Humanitarian Law (IHL), given the grave concerns about the conduct and consequences of the war in Gaza for civilians. The review assessed IHL compliance across three areas: humanitarian provision and access, treatment of detainees and the conduct of the military campaign. The review found possible breaches of IHL in the areas of humanitarian access and in the treatment of detainees. The lack of sufficient verifiable evidence meant that we could not determine whether possible breaches of IHL in the conduct of the campaign had been committed. However, concerns regarding Israel's compliance and commitment in the areas of humanitarian relief and treatment of detainees give cause for concern about its attitude and approach to the conduct of hostilities. The scale of the destruction and the number of civilian deaths also cause great concern. The UK's robust export licensing criteria states that the Government will not issue export licences if there is a clear risk that the items might be used to commit or facilitate serious violations of IHL. Given the conclusions of the review, on 2 September the Government suspended around 30 export licences to Israel, effectively covering all arms exports for use in the current conflict in Gaza, exempting components for F-35 aircraft which, for reasons outlined in the Foreign Secretary's Statement and the Business and Trade Secretary's Written Ministerial Statement, have been excluded from the suspension.